Bio View (Israel) Performance
| BIOV Stock | ILS 15.20 0.80 5.00% |
The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bio View's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio View is expected to be smaller as well. At this point, Bio View has a negative expected return of -0.78%. Please make sure to confirm Bio View's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Bio View performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bio View has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -740 K |
Bio |
Bio View Relative Risk vs. Return Landscape
If you would invest 2,220 in Bio View on September 15, 2025 and sell it today you would lose (700.00) from holding Bio View or give up 31.53% of portfolio value over 90 days. Bio View is generating negative expected returns and assumes 4.4421% volatility on return distribution over the 90 days horizon. Simply put, 39% of stocks are less volatile than Bio, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bio View Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio View's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio View, and traders can use it to determine the average amount a Bio View's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1752
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIOV |
Estimated Market Risk
| 4.44 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.78 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bio View is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio View by adding Bio View to a well-diversified portfolio.
Bio View Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio View, and Bio View fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M | |||
| EBITDA | 4.72 M | |||
| Cash And Equivalents | 17.67 M | |||
| Cash Per Share | 1.24 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 11.80 % | |||
| Book Value Per Share | 2.00 X | |||
| Cash Flow From Operations | 3.25 M | |||
| Earnings Per Share | 0.09 X | |||
| Total Asset | 40.02 M | |||
| Retained Earnings | (29 M) | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
About Bio View Performance
By analyzing Bio View's fundamental ratios, stakeholders can gain valuable insights into Bio View's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio View has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio View has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel.Things to note about Bio View performance evaluation
Checking the ongoing alerts about Bio View for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio View help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio View generated a negative expected return over the last 90 days | |
| Bio View has high historical volatility and very poor performance | |
| About 52.0% of the company shares are held by company insiders |
- Analyzing Bio View's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio View's stock is overvalued or undervalued compared to its peers.
- Examining Bio View's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio View's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio View's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio View's stock. These opinions can provide insight into Bio View's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |